Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio De Filippis

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Expert Opinion on Pharmacotherapy|October 4, 2016
Starting aripiprazole long-acting-once-a-month early in treatment: why, how and for whom? Expert consensus and practical recommendations by a panel of Italian cliniciansGiovanni Amodeo, Chiara Candiracci, Ilaria Capecci, et al.
Frontiers in Psychiatry|November 22, 2021
Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective StudyGiulio Perugi, Paola Calò, Sergio De Filippis, et al.
Current Neuropharmacology|January 17, 2025
Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use DisorderGiada Trovini, Ginevra Lombardozzi, Georgios D Kotzalidis, et al.
Frontiers in Psychiatry|January 24, 2020
Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory AnalysisGloria Giordano, Lorenzo Tomassini, Ilaria Cuomo, et al.
Current Neuropharmacology|March 11, 2022
Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related TraumaSergio De Filippis, Ginevra Lombardozzi, Marta Matrone, et al.
Therapeutic Advances in Psychopharmacology|March 4, 2017
Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? A naturalistic studySergio De Filippis, Ilaria Cuomo, Georgios D Kotzalidis, et al.
Annals of General Psychiatry|August 10, 2022
Mental health in Italy after two years of COVID-19 from the perspective of 1281 Italian physicians: looking back to plan forwardAlessandro Cuomo, Mario Amore, Maria Felice Arezzo, et al.
Journal of Psychiatric Practice|March 19, 2014
Neurological soft signs discriminate schizophrenia from bipolar disorderSilvia Rigucci, Giorgia Dimitri-Valente, Gabriele Mandarelli, et al.
Neuropsychiatric Disease and Treatment|April 17, 2010
Psychiatric comorbidity and suicide risk in patients with chronic migraineMaurizio Pompili, Gianluca Serafini, Daniela Di Cosimo, et al.
The Journal of Headache and Pain|December 20, 2005
Cytotoxic T lymphocyte antigen 4 polymorphism 49 (A>G) and migrainePatrizia Lulli, Simonetta Trabace, Marina Morellini, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Expert Opinion on Pharmacotherapy|October 4, 2016
Starting aripiprazole long-acting-once-a-month early in treatment: why, how and for whom? Expert consensus and practical recommendations by a panel of Italian cliniciansGiovanni Amodeo, Chiara Candiracci, Ilaria Capecci, et al.
Frontiers in Psychiatry|November 22, 2021
Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective StudyGiulio Perugi, Paola Calò, Sergio De Filippis, et al.
Current Neuropharmacology|January 17, 2025
Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use DisorderGiada Trovini, Ginevra Lombardozzi, Georgios D Kotzalidis, et al.
Frontiers in Psychiatry|January 24, 2020
Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory AnalysisGloria Giordano, Lorenzo Tomassini, Ilaria Cuomo, et al.
Current Neuropharmacology|March 11, 2022
Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related TraumaSergio De Filippis, Ginevra Lombardozzi, Marta Matrone, et al.
Therapeutic Advances in Psychopharmacology|March 4, 2017
Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? A naturalistic studySergio De Filippis, Ilaria Cuomo, Georgios D Kotzalidis, et al.
Annals of General Psychiatry|August 10, 2022
Mental health in Italy after two years of COVID-19 from the perspective of 1281 Italian physicians: looking back to plan forwardAlessandro Cuomo, Mario Amore, Maria Felice Arezzo, et al.
Journal of Psychiatric Practice|March 19, 2014
Neurological soft signs discriminate schizophrenia from bipolar disorderSilvia Rigucci, Giorgia Dimitri-Valente, Gabriele Mandarelli, et al.
Neuropsychiatric Disease and Treatment|April 17, 2010
Psychiatric comorbidity and suicide risk in patients with chronic migraineMaurizio Pompili, Gianluca Serafini, Daniela Di Cosimo, et al.
The Journal of Headache and Pain|December 20, 2005
Cytotoxic T lymphocyte antigen 4 polymorphism 49 (A>G) and migrainePatrizia Lulli, Simonetta Trabace, Marina Morellini, et al.
Pageof 7